German Diabetes Center

ENDRA Life Sciences Reports Second Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
Monday, August 14, 2023
Health, Other Science, Clinical Trials, Research, Science, Biotechnology, Proton, Fatty liver disease, EASL, International, Magnetic resonance, De novo, Classification, Marketing, German Diabetes Center, IP, Sale, Trial of the century, Congress, MRI, PIN, Non-alcoholic fatty liver disease, NDRA, Patient, NAFLD, European Association for the Study of the Liver, FDA, Magnetic resonance imaging, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pearson, Food, Medical imaging, Security (finance), Liver

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three and six months ended June 30, 2023 and provided a business update.

Key Points: 
  • ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three and six months ended June 30, 2023 and provided a business update.
  • Highlights from the second quarter of 2023 and recent weeks include:
    Submitted a De Novo Request to the U.S. Food and Drug Administration (FDA) for the TAEUS liver system.
  • During the second quarter, ENDRA secured four additional patents, including one in the U.S. and three in China.
  • Net loss in the second quarter of 2023 was $2.6 million, or $0.43 per share, compared with a net loss of $3.6 million, or $1.17 per share, in the second quarter of 2022.

Patient Monitoring Devices Market Size to Reach USD 92.40 Billion in 2030 | Emergen Research

Retrieved on: 
Tuesday, January 17, 2023
National Association Medical Staff Services, Megasphaera, Honeywell, German Diabetes Center, World Health Organization, Kidney disease, DDZ, Temperature, National Center for Biotechnology Information, COVID-19, WHO, Blood pressure, GE Healthcare, Sinusitis, Health, Risk, Conditional sentence, Growth, Intel, National Center for Health Research, Prevalence, Diabetes, Masimo, Patient, Research, Cancer, Stroke, Kidney, Incidence, USD, Atherosclerosis, Pharmaceutical industry, Medtronic, Biotronik

VANCOUVER, BC, Jan. 17, 2023 /PRNewswire/ -- The patient monitoring devices market size reached USD 47 Billion in 2021 and is expected to register a CAGR of 7.8% during the forecast period, according to latest analysis by Emergen Research .

Key Points: 
  • VANCOUVER, BC, Jan. 17, 2023 /PRNewswire/ -- The patient monitoring devices market size reached USD 47 Billion in 2021 and is expected to register a CAGR of 7.8% during the forecast period, according to latest analysis by Emergen Research .
  • The patient monitoring devices market is expected to register a CAGR of 7.8% over the forecast period and revenue is projected to increase from USD 47.00 Billion in 2021 to USD 92.40 Billion in 2030. is expected to support revenue growth of the market.
  • The major factors for market expansion are the incidence of chronic diseases, favorable reimbursement circumstances, and rising awareness of patient monitoring devices.
  • Given the increasing research and development efforts by global market players to produce cutting-edge patient monitoring devices, the market revenue is expected to grow.

Patient Monitoring Devices Market Size to Reach USD 92.40 Billion in 2030 | Emergen Research

Retrieved on: 
Tuesday, January 17, 2023
National Association Medical Staff Services, Megasphaera, Honeywell, German Diabetes Center, World Health Organization, Kidney disease, DDZ, Temperature, National Center for Biotechnology Information, COVID-19, WHO, Blood pressure, GE Healthcare, Sinusitis, Health, Risk, Conditional sentence, Growth, Intel, National Center for Health Research, Prevalence, Diabetes, Masimo, Patient, Research, Cancer, Stroke, Kidney, Incidence, USD, Atherosclerosis, Pharmaceutical industry, Medtronic, Biotronik

VANCOUVER, BC, Jan. 17, 2023 /PRNewswire/ -- The patient monitoring devices market size reached USD 47 Billion in 2021 and is expected to register a CAGR of 7.8% during the forecast period, according to latest analysis by Emergen Research .

Key Points: 
  • VANCOUVER, BC, Jan. 17, 2023 /PRNewswire/ -- The patient monitoring devices market size reached USD 47 Billion in 2021 and is expected to register a CAGR of 7.8% during the forecast period, according to latest analysis by Emergen Research .
  • The patient monitoring devices market is expected to register a CAGR of 7.8% over the forecast period and revenue is projected to increase from USD 47.00 Billion in 2021 to USD 92.40 Billion in 2030. is expected to support revenue growth of the market.
  • The major factors for market expansion are the incidence of chronic diseases, favorable reimbursement circumstances, and rising awareness of patient monitoring devices.
  • Given the increasing research and development efforts by global market players to produce cutting-edge patient monitoring devices, the market revenue is expected to grow.

alytas therapeutics collaborates with spin-off from the German Diabetes Center

Retrieved on: 
Monday, November 28, 2022
German Diabetes Center, Antibody, Metabolism, Cardiovascular disease, Patient, Annual report, Homeostasis, Adipose tissue, Diabetes, Cancer, Research, Therapy, Obesity, Antigen, Vaccine

Xlife Sciences (SIX: XLS) portfolio company alytas therapeutics (located in Jena, Germany) explores innovative, antibody-based therapeutic concepts for treatment of morbid obesity.

Key Points: 
  • Xlife Sciences (SIX: XLS) portfolio company alytas therapeutics (located in Jena, Germany) explores innovative, antibody-based therapeutic concepts for treatment of morbid obesity.
  • To conduct a deep functional in vitro characterization of recently identified antibodies, alytas therapeutics and CureDiab Metabolic Research have signed a research contract.
  • As a spin-off from the German Diabetes Center in Duesseldorf, CureDiab is able to use the excellent lab infrastructure and expertise regarding adipose tissue metabolism.
  • We highly appreciate the collaboration with alytas therapeutics and look forward to an exciting scientific project.

D&D Pharmatech Announces First Patient Dosed in Phase 1 Clinical Trial of DD01 in Obese Patients with Diabetes and NAFLD

Retrieved on: 
Tuesday, March 30, 2021
Health, Diabetes, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Medical specialties, Anatomy, Clinical medicine, Hepatitis, Non-alcoholic fatty liver disease, Fatty liver disease, Obesity, Diabetes, Liver disease, German Diabetes Center, Insulin resistance, DD01, D&D Pharmatech

D&D Pharmatech, Inc. (D&D), a clinical-stage biotechnology company focused on the development of disease-modifying drugs, today announced dosing of the first patient in a Phase 1 clinical trial of DD01 in obese patients with diabetes and non-alcoholic fatty liver disease (NAFLD).

Key Points: 
  • D&D Pharmatech, Inc. (D&D), a clinical-stage biotechnology company focused on the development of disease-modifying drugs, today announced dosing of the first patient in a Phase 1 clinical trial of DD01 in obese patients with diabetes and non-alcoholic fatty liver disease (NAFLD).
  • In preclinical models of obesity, diabetes and NAFLD, DD01 treatment reduced weight and improved blood sugar.
  • The effect of DD01 persisted after cessation of treatment suggesting disease-modifying effects contribute to its efficacy.
  • The trial is designed to assess safety, pharmacokinetics and pharmacodynamic effects of DD01 in subjects with obesity, diabetes and NAFLD.

Second year of the Montreal Heart Institute's Diabetes Prevention Clinic sponsored by Sun Life

Retrieved on: 
Thursday, January 14, 2021
Health, Medicine, Diabetes, Disability, Preventive healthcare, Coronavirus disease, German Diabetes Center

MONTREAL, Jan. 14, 2021 /CNW/ - When the pandemic forced gyms to close, it caused some disruption to the plans that had been developed for patients by the team at the Montreal Heart Institute's Diabetes Prevention Clinic sponsored by Sun Life.

Key Points: 
  • MONTREAL, Jan. 14, 2021 /CNW/ - When the pandemic forced gyms to close, it caused some disruption to the plans that had been developed for patients by the team at the Montreal Heart Institute's Diabetes Prevention Clinic sponsored by Sun Life.
  • "The pandemic has highlighted the consequences of diabetes, which can cause severe complications in people with the disease who contract COVID-19.
  • The Diabetes Prevention Clinic's mission is to turn the tide on diabetes through early detection and healthy lifestyle strategies.
  • The Center has just over 100 employees and is part of the Prevention Branch of the Montreal Heart Institute.

New voices chosen to elevate the link between type 2 diabetes, heart disease and stroke

Retrieved on: 
Monday, November 16, 2020
Diabetes, Organ systems, Health, Clinical medicine, Type 2 diabetes, American Diabetes Association, Type 1 diabetes, International Diabetes Center at Park Nicollet, German Diabetes Center

Representing diverse backgrounds and geographies, the new Know Diabetes by Heart ambassadors were chosen followinga nationwide search for inspiring people with relatable type 2 diabetes health journeys.

Key Points: 
  • Representing diverse backgrounds and geographies, the new Know Diabetes by Heart ambassadors were chosen followinga nationwide search for inspiring people with relatable type 2 diabetes health journeys.
  • A good way to get started is by talking with your health care provider about managing your risk for heart disease and stroke at your next appointment."
  • Karen Dawson (Victorville, CA) Karen, 60, a health care professional, knew she could thrive with type 2 diabetes if she managed it well.
  • The American Heart Association and the American Diabetes Association launched the collaborative landmark initiative called Know Diabetes by Heart to comprehensively combat the national public health impact of type 2 diabetes and cardiovascular disease.

ACC, Novo Nordisk Partner to Improve Cardiovascular Disease Management in Patients with Type 2 Diabetes

Retrieved on: 
Thursday, September 10, 2020
Diabetes, Health, Articles, Organ systems, Type 2 diabetes, Preventive healthcare, German Diabetes Center, Diabetes management

1 cause of death among patients with Type 2 diabetes.

Key Points: 
  • 1 cause of death among patients with Type 2 diabetes.
  • "This initiative will be critical to achieving a progressive path forward in the management of cardiovascular risk in Type 2 diabetes."
  • Creating individualized management and prevention strategies for people with Type 2 diabetes has become increasingly complex, especially when physicians have to navigate new clinical guidelines, pathways and novel therapy choices.
  • "We're looking forward to learning through this research, alongside our ACC partners, and implementing a program that can help improve the quality of care for people with Type 2 diabetes and cardiovascular disease."